| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/03/2012 | CA2643972C Hepoxilin analog enantiomers |
| 01/03/2012 | CA2640402C Alpha-2-delta ligands for non-restorative sleep |
| 01/03/2012 | CA2636077C Thiazole compounds as protein kinase b (pkb) inhibitors |
| 01/03/2012 | CA2632556C Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
| 01/03/2012 | CA2632194C N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
| 01/03/2012 | CA2628794C Treatment of length dependent neuropathy |
| 01/03/2012 | CA2623603C Immobilizing objects in the body |
| 01/03/2012 | CA2622639C Hiv integrase inhibitors |
| 01/03/2012 | CA2615173C Sustained release enhanced lipolytic formulation for regional adipose tissue treatment |
| 01/03/2012 | CA2601508C Cyclopropanecarboxamide derivatives |
| 01/03/2012 | CA2598786C Composition and method for increasing the anabolic state of muscle cells |
| 01/03/2012 | CA2579619C Radio-opaque polymeric biomaterials |
| 01/03/2012 | CA2576256C Immunomodulating oxopyrrazolocinnolines as cd80 inhibitors |
| 01/03/2012 | CA2558245C An improved process for the preparation of n-([1,2,4]triazolopyrimidin-2-yl)aryl sulfonamides |
| 01/03/2012 | CA2544720C The use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person |
| 01/03/2012 | CA2542102C Indole antiviral compositions and methods |
| 01/03/2012 | CA2541752C Crystalline form of gamma-aminobutyric acid analog |
| 01/03/2012 | CA2537702C Methods for the treatment of endometriosis |
| 01/03/2012 | CA2536257C Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
| 01/03/2012 | CA2530310C Substituted diketopiperazines and their use as oxytocin antagonists |
| 01/03/2012 | CA2529464C Propionamide derivatives useful as androgen receptor modulators |
| 01/03/2012 | CA2528656C 5ht4-antagonistic 4-(aminomethyl)-piperidine benzamides |
| 01/03/2012 | CA2528160C Use of 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine for neuronal regeneration and functional recovery |
| 01/03/2012 | CA2524525C Novel pyridopyrazines and use thereof as kinase modulators |
| 01/03/2012 | CA2515132C Heteroaryl substituted pyrroles useful as inhibitors of protein kinases |
| 01/03/2012 | CA2514873C Compositions and methods for inhibiting tumor growth and metastasis |
| 01/03/2012 | CA2514407C Thienopyrimidine compounds and use thereof |
| 01/03/2012 | CA2513752C Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors |
| 01/03/2012 | CA2512441C Thienopyrimidinediones and their use in the modulation of autoimmune disease |
| 01/03/2012 | CA2512434C Sustained-release pharmaceutical composition comprising carrageenan for lung administration |
| 01/03/2012 | CA2506962C Synergistic combination comprising roflumilast and formoterol |
| 01/03/2012 | CA2505183C Substituted quinazolines as antiviral agents, especially against cytomegaloviruses |
| 01/03/2012 | CA2504846C Antiviral nucleoside derivatives |
| 01/03/2012 | CA2501610C Epothilone derivatives for the treatment of multiple myeloma |
| 01/03/2012 | CA2499622C Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders |
| 01/03/2012 | CA2498506C Novel pharmaceutical formulations of modafinil |
| 01/03/2012 | CA2496902C Medicament for activating the phagocytic capacity of macrophages |
| 01/03/2012 | CA2495060C Derivatives of pyrrolo-pyrazines having a kinase inhibitory activity and their biological applications |
| 01/03/2012 | CA2495058C C6- and c9-substituted isoxazoline derivatives and their use as anti-depressants |
| 01/03/2012 | CA2491612C 4-'7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents |
| 01/03/2012 | CA2491216C Method of producing a cationic liposomal preparation comprising a lipophilic compound |
| 01/03/2012 | CA2490200C 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
| 01/03/2012 | CA2489128C 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections |
| 01/03/2012 | CA2488565C Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom |
| 01/03/2012 | CA2486712C Method of treating diabetes |
| 01/03/2012 | CA2484184C Minoxidil foam formulation |
| 01/03/2012 | CA2481321C [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
| 01/03/2012 | CA2480356C Benzamide derivatives useful as histone deacetylase inhibitors |
| 01/03/2012 | CA2468910C Use of 4-oxobutanoic acid derivatives in the treatment of inflammation |
| 01/03/2012 | CA2466054C Apo-2 ligand/trail formulations |
| 01/03/2012 | CA2465117C Lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases |
| 01/03/2012 | CA2464309C Combinations comprising a selective cyclooxygenase-2 inhibitor |
| 01/03/2012 | CA2463974C Dendrimers for use in targeted delivery |
| 01/03/2012 | CA2463134C Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| 01/03/2012 | CA2457719C Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 01/03/2012 | CA2456717C Phenyl derivatives as factor xa inhibitors |
| 01/03/2012 | CA2455972C N6-benzyl and phenyl substituted adenines and their use as cosmetics, pharmaceutical preparations and plant growth regulators |
| 01/03/2012 | CA2453243C Treatment of nail infections with no |
| 01/03/2012 | CA2452151C Use of cyclopamine, an inducer of the differentiation and apoptosis of the basal cell carcinoma (bcc) cells, in the treatment of bcc's and other tumors that use the hedgehog/smoothened pathway for proliferation of apoptosis |
| 01/03/2012 | CA2446837C Stable high-concentration injection containing pyrazolone derivative |
| 01/03/2012 | CA2446254C New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits |
| 01/03/2012 | CA2445835C 6h-oxazolo[4,5-e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands |
| 01/03/2012 | CA2436049C A serpin in bifidobacteria |
| 01/03/2012 | CA2432020C Coenzyme q products exhibiting high dissolution qualities |
| 01/03/2012 | CA2428728C Combination antiperspirant and antimicrobial compositions |
| 01/03/2012 | CA2423220C Modified prodrug forms of ap/amp |
| 01/03/2012 | CA2420618C Percarboxylated polysaccharides, and a process for their preparation |
| 01/03/2012 | CA2408023C Glucosamine as a food and beverage additive |
| 01/03/2012 | CA2399293C Optically-active nanoparticles for use in therapeutic and diagnostic methods |
| 01/03/2012 | CA2397661C 2,4-disubstituted thiazolyl derivatives |
| 01/03/2012 | CA2397018C Compounds exhibiting thrombopoietin receptor agonism |
| 01/03/2012 | CA2395684C Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 01/03/2012 | CA2388180C Inhibitors of the inositol polyphosphate 5-phosphatase ship2 molecule |
| 01/03/2012 | CA2334960C Combination of tgf-.beta. inhibition and immune stimulation to treat hyperproliferative diseases |
| 01/03/2012 | CA2331257C Use of tetracyclines for treating meibomian gland disease |
| 01/03/2012 | CA2261346C Polynucleotide vaccine formula for treating porcine respiratory and reproductive diseases |
| 01/03/2012 | CA2260855C Polynucleotide vaccine formula in particular against bovine respiratory pathology |
| 01/03/2012 | CA2236591C Continuous low-dose cytokine infusion therapy |
| 01/03/2012 | CA2229811C Inverted chimeric and hybrid oligonucleotides |
| 01/03/2012 | CA2227265C Methods and compositions useful for inhibition of .alpha.v.beta.5 mediated angiogenesis |
| 01/03/2012 | CA2226973C Modulators of the function of fas receptors and other proteins |
| 01/03/2012 | CA2224468C P53 protein variants and therapeutical uses thereof |
| 01/03/2012 | CA2222889C Improved formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| 01/03/2012 | CA2210998C Inhibition of neovascularization using vegf-specific oligonucleotides |
| 01/03/2012 | CA2209771C Combined therapeutical treatment of hyperproliferative diseases |
| 01/02/2012 | CA2745113A1 Nutritional or dietary supplement composition and methods for using same for treating visual acuity loss |
| 12/29/2011 | WO2011163640A1 C5ar antagonists |
| 12/29/2011 | WO2011163636A2 Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms |
| 12/29/2011 | WO2011163619A1 Niacin mimetics, and methods of use thereof |
| 12/29/2011 | WO2011163617A1 Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis |
| 12/29/2011 | WO2011163614A2 Methods of treatment for esophageal inflammation |
| 12/29/2011 | WO2011163612A1 Niacin mimetics, and methods of use thereof |
| 12/29/2011 | WO2011163610A2 Antimicrobial agents |
| 12/29/2011 | WO2011163600A2 Tacrolimus compositions for aerosol administration |
| 12/29/2011 | WO2011163594A2 Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| 12/29/2011 | WO2011163560A1 Methods of treatment using sterculic acid |
| 12/29/2011 | WO2011163554A2 Lipocalin-type prostaglandin d2 synthase as a biomarker for lung cancer progression and prognosis |
| 12/29/2011 | WO2011163527A1 Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
| 12/29/2011 | WO2011163518A1 Pyrazolo [1, 5 -a] pyrimidines as antiviral agents |
| 12/29/2011 | WO2011163502A1 Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |